CJC-1295 No DAC, commonly referred to as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic 29-amino-acid analogue of Growth Hormone-Releasing Hormone (GHRH).

It has been developed to stimulate the GHRH receptor in the anterior pituitary, producing endogenous growth-hormone (GH) release. Unlike CJC-1295 with DAC, the No-DAC form does not contain the albumin-binding Drug Affinity Complex responsible for the prolonged activity of DAC-containing CJC-1295.

Key Research Areas

Growth Hormone Secretion
The primary research interest surrounding Modified GRF (1-29) is its interaction with the GHRH receptor and subsequent stimulation of pituitary GH secretion.

This pathway makes the compound relevant to research examining:

• Growth hormone secretion
• GH pulse physiology
• GH/IGF-1 signalling
• Pituitary function
• Endocrine regulation
• Metabolic signalling

GH/IGF-1 Axis Research
Growth hormone stimulates production of Insulin-Like Growth Factor-1 (IGF-1), creating the well-known GH/IGF-1 endocrine axis.

Research involving long-acting DAC-containing CJC-1295 has demonstrated substantial increases in both GH and IGF-1 in healthy adults. However, these human results should not be directly attributed to CJC-1295 No DAC, because the DAC modification dramatically changes the compound’s pharmacokinetics.

Pulsatile GH Research
Natural growth hormone secretion occurs in pulses rather than remaining continuously elevated.

Because CJC-1295 No DAC lacks the albumin-binding modification, it is considerably shorter acting than DAC-containing CJC-1295. This makes Modified GRF (1-29) particularly interesting for laboratory research investigating short-duration GHRH receptor activation and pulsatile GH signalling.

Metabolic & Body-Composition Research
The GH/IGF-1 pathway has important physiological roles in:

• Lipid metabolism
• Protein metabolism
• Glucose regulation
• Skeletal-muscle physiology
• Bone metabolism
• Body composition